The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Molecular features underlying response to neoadjuvant gemcitabine, cisplatin, and sorafenib (S-GC) in muscle-invasive urothelial bladder carcinoma (MIBC): Insights for trials of new agents combined with chemotherapy in the field.
 
Andrea Necchi
Consulting or Advisory Role - AstraZeneca; Bayer; Merck Sharp & Dohme; Roche
Research Funding - Amgen (Inst); AstraZeneca (Inst); Merck Sharp & Dohme (Inst)
Travel, Accommodations, Expenses - Merck Sharp & Dohme; Pierre Fabre; Roche
 
Daniele Raggi
No Relationships to Disclose
 
Adele Busico
No Relationships to Disclose
 
Loris De Cecco
No Relationships to Disclose
 
Patrizia Giannatempo
No Relationships to Disclose
 
Nicola Nicolai
No Relationships to Disclose
 
Luigi Piva
No Relationships to Disclose
 
Davide Biasoni
No Relationships to Disclose
 
Mario Catanzaro
No Relationships to Disclose
 
Tullio Torelli
No Relationships to Disclose
 
Silvia Stagni
No Relationships to Disclose
 
Giuseppina Calareso
No Relationships to Disclose
 
Elena Togliardi
No Relationships to Disclose
 
Maurizio Colecchia
No Relationships to Disclose
 
Luigi Mariani
No Relationships to Disclose
 
Roberto Salvioni
No Relationships to Disclose
 
Alessandro Paoli
No Relationships to Disclose
 
Maria Grazia Daidone
No Relationships to Disclose
 
Marialuisa Sensi
No Relationships to Disclose
 
Federica Perrone
No Relationships to Disclose